MG
RDY icon

Michael Gelband’s Dr. Reddy's Laboratories RDY Stock Holding History

Michael Gelband’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,915
Closed -$282K – 2047
2022
Q3 		$282K Buy
26,915
+7,415
+38% +$79K ﹤0.01% 1540
2022
Q2 		$216K Buy
19,500
+850
+5% +$9.24K ﹤0.01% 1637
2022
Q1 		$208K Buy
+18,650
New +$211K ﹤0.01% 1898
2020
Q1 		– Sell
-61,305
Closed -$498K – 1549
2019
Q4 		$498K Buy
+61,305
New +$484K 0.01% 858

Other funds holding RDY

Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Michael Gelband's RDY Position: Q4 2022 in Review

Michael Gelband sold out of Dr. Reddy's Laboratories (RDY) in Q4 2022, closing a stake of 26,915 shares — an estimated $282K sold.

Michael Gelband first reported a position in RDY in Q4 2019 and held it in 4 quarters. The position peaked at $498K in Q4 2019. 162 funds tracked by Wall St. Rank hold RDY as of Q4 2022.

  • Michael Gelband reported no remaining Dr. Reddy's Laboratories position as of Q4 2022 after selling out during the quarter.
  • Michael Gelband sold 26,915 Dr. Reddy's Laboratories shares in Q4 2022, an estimated $282K.
  • Michael Gelband first reported a position in Dr. Reddy's Laboratories in Q4 2019 and held it in 4 quarters.
  • Michael Gelband's Dr. Reddy's Laboratories position peaked at $498K in Q4 2019.
  • 162 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q4 2022.

Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.